Literature DB >> 27731522

The novel treatment of SVF-enriched fat grafting for painful end-neuromas of superficial radial nerve.

Maurizio Calcagni1, Simon Zimmermann1, Mario F Scaglioni1, Thomas Giesen1, Pietro Giovanoli1, Richard M Fakin1.   

Abstract

INTRODUCTION: None of the existing treatments in the management of painful end-neuromas of the superficial branch of the radial nerve (SBRN) has been proven superior due to high levels of pain relapse. Fat grafts enriched with the stromal vascular fraction (SVF) could act as a mechanic barrier with biological effects decreasing the resorption rate and boosting the graft's regenerative potential. This study describes the novel surgical treatment technique of SVF-enriched fat grafting. PATIENTS AND METHODS: In this clinical study, five consecutive patients treated for painful end-neuromas of the SBRN between 2012 and 2013 were analyzed retrospectively. Microsurgical resection of end-neuromas followed by SVF-enriched fat grafting around the nerve stump was performed in all patients. Five different pain modalities and various predictors were compared pre- and up to 36 months postoperatively.
RESULTS: Pain reduction observed at 2 months after surgery was constant over time, though not statistically significant compared to preoperative levels. Spontaneous pain could be reduced from 1.6 ± 0.55 to 1.2 ± 1.1 (p = 0.414), spikes from 2.2 ± 1.3 to 1.4 ± 1.34 (p = 0.180), hyperaesthesia from 1.6 ± 1.14 to 1.2 ± 1.64 (p = 0.713), tap pain from 2.8 ± 0.45 to 1.8 ± 1.3 (p = 0.197) and motion pain from 2.8 ± 0.45 to 1.4 ± 1.34 (p = 0.066). An improvement in overall pain reduction could be observed from 2.2 ± 0.97 to 1.4 ± 1.26 3 years after the surgery (p = 0.104).
CONCLUSION: SVF-enriched fat grafting represents another alternative to numerous available treatments of painful end-neuromas of the SBRN. Our preliminary results could not show any significant difference in pain reduction following SVF-enriched fat grafting. Further larger trials are required in order to evaluate the therapeutic potential of SVF-enriched fat grafting.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27731522     DOI: 10.1002/micr.30122

Source DB:  PubMed          Journal:  Microsurgery        ISSN: 0738-1085            Impact factor:   2.425


  6 in total

1.  Stromal Vascular Fraction-enriched Fat Grafting for the Treatment of Symptomatic End-neuromata.

Authors:  Simon Zimmermann; Richard M Fakin; Thomas Giesen; Pietro Giovanoli; Maurizio Calcagni
Journal:  J Vis Exp       Date:  2017-11-23       Impact factor: 1.355

2.  Isolation of Murine Adipose Tissue-derived Microvascular Fragments as Vascularization Units for Tissue Engineering.

Authors:  Florian S Frueh; Thomas Später; Claudia Scheuer; Michael D Menger; Matthias W Laschke
Journal:  J Vis Exp       Date:  2017-04-30       Impact factor: 1.355

3.  Outcome of Stromal Vascular Fraction-Enriched Fat Grafting Compared to Intramuscular Transposition in Painful End-Neuromas of Superficial Radial Nerve: Preliminary Results.

Authors:  Simon Zimmermann; Richard M Fakin; Pietro Giovanoli; Maurizio Calcagni
Journal:  Front Surg       Date:  2018-02-16

4.  The Role of Fat Grafting in Alleviating Neuropathic Pain: A Critical Review of the Literature.

Authors:  Mario Alessandri-Bonetti; Francesco M Egro; Paolo Persichetti; Sydney R Coleman; J Peter Rubin
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-05-21

5.  Concise Review: A Safety Assessment of Adipose-Derived Cell Therapy in Clinical Trials: A Systematic Review of Reported Adverse Events.

Authors:  Navid Mohamadpour Toyserkani; Mads Gustaf Jørgensen; Siavosh Tabatabaeifar; Charlotte Harken Jensen; Søren Paludan Sheikh; Jens Ahm Sørensen
Journal:  Stem Cells Transl Med       Date:  2017-07-19       Impact factor: 6.940

6.  Predictive value of a diagnostic block in focal nerve injury with neuropathic pain when surgery is considered.

Authors:  Martijn J A Malessy; Ralph de Boer; Ildefonso Muñoz Romero; Job L A Eekhof; Erik W van Zwet; Michel Kliot; Albert Dahan; Willem Pondaag
Journal:  PLoS One       Date:  2018-09-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.